Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.73 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.73 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.65 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12190818 | 0.91 | CHRNB4 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL8554893 | 0.86 | CHRNB2 (0.71) | CHRNB2CHRNA4 | |
| SCHEMBL8552275 | 0.86 | CHRNB2 (0.71) | CHRNB2CHRNA4 | |
| SCHEMBL14941167 | 0.85 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| Hydrochloric Acid SCHEMBL7407781 | 0.85 | CHRNB2 (0.70) | CHRNB2CHRNA4 | |
| SCHEMBL14941214 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941212 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941414 | 0.84 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941018 | 0.83 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL14941016 | 0.83 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885CHRNB4 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.